- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
EN
A
RCUS
Arcus Bioscience
22.65
+0.58+2.63%Pre Market: 22.15 -0.50 -2.21%07:24 04/09 EDT
OPEN/PREV CLOSE22.70/22.07
TODAY RANGE22.17-23.17
VOL17
MARKET CAP2.84B
52 WEEK RANGE6.50-26.40
AVG VOL (3M)1.19M
% TURNOVER0.85%
TURNOVER0
P/E (TTM)-6.8912
% RANGE4.49%
EPS(TTM)-3.2868
P/E(FORWARD)-6.0724
P/B4.498
BVPS5.04
DIVIDEND--
P/S11.49
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.99B
SHARES OUTSTANDING125.35M
NEXT EARNINGS05/04-05/08
FREE FLOAT88.04M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·6d ago
Arcus Biosciences Is Maintained at Outperform by Wedbush
Simply Wall St·03/27 23:07
Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound
TipRanks·03/24 15:25
Mizuho Securities Remains a Buy on Arcus Biosciences (RCUS)
Dow Jones·03/23 12:37
Damora Therapeutics Names Jennifer Jarrett as CEO
TipRanks·03/23 12:24
Arcus Biosciences Announces COO Resignation and Transition Plan
TipRanks·03/23 12:15
Damora Therapeutics appoints Jennifer Jarrett as CEO
Simply Wall St·03/11 00:37
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion
Simply Wall St·03/09 08:12
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings
Simply Wall St·03/06 02:34
Arcus Biosciences Casdatifan Data Reshapes Kidney Cancer And Valuation Story
Dow Jones·03/05 19:43
Arcus Biosciences Price Target Raised to $45.00/Share From $44.00 by Citigroup
Dow Jones·03/05 19:43
Arcus Biosciences Is Maintained at Buy by Citigroup
Benzinga·03/05 19:34
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $45
Same Industry
Name/Symbol
Change%
Price